Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTEND: Extended Drotrecogin Alfa in Severe Sepsis
NCT00190788Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of drotrecogin alfa in sepsis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Resolution of vasopressor-dependent hypotension up to 72 hours. Started Jun 2004; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT00190788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00190788.